// App-Quantinova.ai

764 : Effect of Pegcetacoplan on Quality of Life in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Pegasus Phase 3 Trial Comparing Pegcetacoplan to Eculizumab

Researchers

Presenter

  • Alexander Rth

Principal Investigators

  • Britta Hoechsmann

  • Morag Griffin

  • Carlos M. de Castro

  • Jeffrey Szer

  • Kensuke Usuki

  • Juliette Soret

  • Mohamed Hamdani

  • Temitayo Ajayi

  • Sujata P. Sarda

  • Jens Panse

Medical Centers

  • Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

  • University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics,German Red Cross Blood Transfusion Service and University Hospital Ulm, Institute of Transfusion Medicine,Ulm,Germany

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • Duke University College of Medicine, Durham, NC

  • Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia

  • Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan

  • Centre d'Investigations Cliniques, Hôpital Saint-Louis; Assistance Publique – Hôpitaux de Paris; Université de Paris, Paris, France

  • AMAG Pharmaceuticals, Inc., Waltham, MA

  • Department of Oncology, Hematology and Stem Cell Transplantation, University Hospital of the RWTH Aachen, Aachen, Germany

Locations

  • Germany

  • United Kingdom

  • United States

  • Australia

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03500549

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved